Authorized purpose: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
Clinical role
Notification-only study triage and prioritization; the product is not a standalone clinical decision tool or a rule-out system.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Chest/Lung; Brain
Key limitation
Keep in mind: Cleared adult use is limited to the listed findings and input requirements. Notifications do not replace image interpretation, are not a standalone clinical decision, and should not be treated as a negative rule-out result.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Chest/Lung; Brain Input: CXR: at least one frontal AP or PA view, with up to three images total and lateral views supported. CTB: non-contrast axial brain CT, up to 1,000 images, slice thickness <=5 mm, using a brain reconstruction kernel or similar.
Who uses it?Intended users: Radiologists and other qualified healthcare professionals interpreting adult chest radiographs and non-contrast brain CT.
What does the software produce?Output: Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.
What is its most important limitation?Key limitation: Cleared adult use is limited to the listed findings and input requirements. Notifications do not replace image interpretation, are not a standalone clinical decision, and should not be treated as a negative rule-out result.
Clinical takeaway. Clinical role: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
Evidence takeaway. Evidence from the reviewed source record: The reviewed FDA summary establishes the multi-modality intended-use and input boundaries for Annalise Enterprise 3.10+ but does not provide a single consolidated performance metric suitable for this dossier.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
CXR: at least one frontal AP or PA view, with up to three images total and lateral views supported. CTB: non-contrast axial brain CT, up to 1,000 images, slice thickness <=5 mm, using a brain reconstruction kernel or similar.
Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.
Cleared adult use is limited to the listed findings and input requirements. Notifications do not replace image interpretation, are not a standalone clinical decision, and should not be treated as a negative rule-out result.
The reviewed FDA summary establishes the multi-modality intended-use and input boundaries for Annalise Enterprise 3.10+ but does not provide a single consolidated performance metric suitable for this dossier.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The reviewed FDA summary establishes the multi-modality intended-use and input boundaries for Annalise Enterprise 3.10+ but does not provide a single consolidated performance metric suitable for this dossier.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CXR: at least one frontal AP or PA view, with up to three images total and lateral views supported. CTB: non-contrast axial brain CT, up to 1,000 images, slice thickness <=5 mm, using a brain reconstruction kernel or similar.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The submission describes study-level integration with the radiology worklist/PACS workflow for notification and prioritization; exact local routing and reader configuration require site confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Annalise Enterprise is described in the FDA submission as software integrated into the imaging workflow; the exact site hosting model for this submission is not established in the public summary.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Study-level abnormality notifications and prioritization information for the listed CXR and brain-CT findings; final interpretation remains with the clinician.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Annalise Enterprise is described in the FDA submission as software integrated into the imaging workflow; the exact site hosting model for this submission is not established in the public summary.
The submission describes study-level integration with the radiology worklist/PACS workflow for notification and prioritization; exact local routing and reader configuration require site confirmation.
The official Comprehensive Care page describes PACS/RIS workflow integration, and the Annalise administration documentation describes configurable PACS/RIS interfaces for the family.
product family · checked 2026-09-07
Connector availability, hosting and configuration for K250831 require vendor/site confirmation; the administration PDF was reviewed via web-rendered/cached fulltext after a direct-fetch 403.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor technical documentation, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission
No public price or quote for K250831 was reviewed.
Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission
License, per-study, subscription and implementation terms were not established.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Annalise Enterprise reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Harrison.ai's 2024-08-02 release announces NTAP for Annalise Obstructive Hydrocephalus; it is not shown to be this entry. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-07 - Exact FDA submission
The reviewed guides describe administration but do not establish site-specific training deliverables for K250831.
Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission
No exact-release clinical performance monitoring or drift program was established.
Authorized purpose: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain, cerebral vasculature, and perfusion regions
Authorized purpose: Rapid Platform v6.0 is image-processing software for trained professionals that views, processes, and analyzes DICOM images from CT and MRI. It supports functional and dynamic datasets including CT perfusion, CT angiography, diffusion-weighted MRI, and dynamic contrast-enhanced CT or MRI, with maps and measurements for tissue perfusion, diffusion, and blood volume. Rapid CT-Perfusion and Rapid MR-Perfusion may aid physicians in selecting acute stroke patients with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery for endovascular thrombectomy, subject to the labeled imaging criteria, clinical requirements, and exclusions.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain and intracranial vessels represented in CT perfusion, CTA, and MRI; tissue perfusion, diffusion, and contrast dynamics
Authorized purpose: Rapid processes CT, CTP, CTA, diffusion MRI, and dynamic-contrast MRI for stroke viewing, perfusion, volumetry, mismatch, and large-vessel-density support for trained professionals.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Neuro.Al Algorithm processes static, functional, dynamic, and derived CT or MR images to support brain perfusion analysis, tissue blood-volume and parametric-map review, ventricular visualization, and DICOM return to clinical viewers for trained professional interpretation.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.